Despite unprecedented global efforts during the last months in the fight of the COVID-19 pandemic, which include more than 500 randomized clinical trials ("Covid-19 living Data," n.d.), neither a preventive vaccine nor an effective treatment as a potential complement to standard supportive care have yet been validated. This situation is more problematic in the case of severe patients, provided increasing clinical reports account for a rather biphasic pathophysiology. In fact, the initial phase of the disease is characterized by a typical virus-driven response, which might subsequently (by day 7--10 after symptom onset) shunt into an acute immunopathologic phase with an associated hypercytokinemia ([@bib15]; [@bib20]; [@bib32]), hence adding more complexity to the choice of a potentially effective treatment. However, such "cytokine storm" is not independent of viral replication but frequently an attempt to clear the viral aggression. In that regard, recent data suggest that high virus titers during the first week of infection could be correlated with a higher probability of moderate to severe clinical outcome ([@bib18]; [@bib31]). This highlights the value of identifying and validating molecules and/or combination of molecules with a strong SARS-CoV-2 antiviral activity for an early and effective reduction of viral load that could ultimately contribute to a more favorable clinical prognosis.

In this context, we sought to assess the *in vitro* antiviral activity of a shortlist of compounds known for their relative broad-spectrum antiviral activities that in our view have a rationale for a putative inhibitory effect against SARS-CoV-2 and, on top of that, could be readily available for further pre-clinical and clinical evaluation. Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamine) is a pyrazine derivative that has demonstrated potent antiviral activity against multiple RNA viruses, being currently approved in Japan for the treatment of influenza infections ([@bib12], [@bib13]). The ribonucleoside analog ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is also known to show broad-spectrum antiviral activity and is used in combination with interferon-α to treat hepatitis C virus infection ([@bib9]; [@bib25]). Umifenovir (Arbidol) is a small indole-derivative molecule, licensed in Russia and China for the prophylaxis and treatment of influenza and other respiratory viral infections ([@bib2]). Berberine is a plant-derived isoquinoline alkaloid, described as having broad antiviral activity, notably against influenza and alphaviruses ([@bib27]; [@bib30]). Cyclosporine A is a widely used immunosuppressant drug also known for its ability to inhibit the replication of several viruses, including several coronaviruses ([@bib10]). Lastly, diltiazem is a voltage gated Ca2+ channel blocker commonly used as anti-hypertensive, which we have recently repurposed as a host-directed inhibitor of influenza virus ([@bib23]).

Molecules were obtained from Sigma-Aldrich and 10 mM stock solutions were prepared in DMSO (favipiravir, lopinavir, remdesivir, umifenovir), ethanol (berberine, cyclosporine A) or water (chloroquine, diltiazem, ribavirin). We therefore performed experimental infections in Vero E6 cells at a multiplicity of infection (MOI) of 0.01 using the BetaCoV/France/IDF0571/2020 SARS-CoV-2 strain, previously isolated from one of the first COVID-19 cases in France. One-hour post infection (hpi), the viral inoculum was removed, and cells were treated with serial dilutions of the candidate molecules in infection media. Dilutions of the corresponding solvents in infection media were used for mock-treated controls. Supernatants were collected 48 hpi for subsequent viral titration by RT-qPCR, as described elsewhere ([@bib22]). Noteworthy, we included the active principles of the three drugs evaluated in the WHO\'s COVID-19 Solidarity Trial ("'[@bib26]' clinical trial for [@bib8]) as comparators: i) remdesivir, an experimental adenosine nucleotide analog prodrug previously evaluated in the context of the 2018 Kivu Ebola epidemic ([@bib21]); ii) lopinavir, a protease inhibitor antiretroviral approved for the treatment of HIV infections ([@bib7]); iii) chloroquine, an aminoquinolone derivative mainly used for the treatment of malaria but also for certain chronic inflammatory diseases such as rheumatoid arthritis and lupus erythematosus ([@bib1]).

[Table 1](#tbl1){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"} recapitulate the main features of the evaluated compounds, including the calculated 50% inhibitory concentration (IC50), 50% cytotoxic concentration (CC50) and selectivity index (SI) values as well as the dose-response curves of the compounds with such an effect. As expected, calculated IC50 values for lopinavir, remdesivir and chloroquine were in the low micromolar range (5.2, 0.99 and 1.38 μM, respectively), with the latter two showing a very favorable SI (278 and 172, respectively), in good agreement with recent reports ([@bib6]; [@bib29]). On the other hand, although their efficacy against influenza viruses was previously validated (data not shown), neither diltiazem nor ribavirin or favipiravir showed antiviral activity against SARS-CoV-2 in the conditions tested. This is not surprising in the case of diltiazem, considering its recently described antiviral properties are mostly based on the capacity to induce type I and III interferon (IFN) antiviral responses ([@bib23]), which are partially abrogated in the Vero E6 cell line ([@bib24]). However, we would *a priori* have expected that broad spectrum inhibitors of viral RNA synthesis ribavirin and favipiravir show at least mild antiviral activity against SARS-CoV-2, notably in the context of preliminary clinical data suggesting a putative benefit of favipiravir for the treatment of COVID-19 patients in comparison with umifenovir ( [@bib4]; [@bib17]). Nonetheless, our results are in line with recent observations by Choy and colleagues ([@bib6]). Interestingly, umifenovir, berberine and cyclosporine A, three compounds previously reported to have broad antiviral activity, displayed dose-dependent antiviral responses against SARS-CoV-2. Umifenovir (IC50: 3.5 μM and SI: 21) was reported to inhibit fusion between the viral envelope and the membrane of the target cell, although the exact mechanism of this inhibition is still not well described. Besides its anti-influenza properties, umifenovir has been shown to inhibit some arthropod-borne flaviviruses, including Zika, West Nile and tick-borne encephalitis virus ([@bib14]). Umifenovir is currently being evaluated in clinical trials against COVID-19 ( [@bib4]; [@bib17]). Berberine (IC50: 10.6 μM and SI: \>37) has demonstrated *in vitro* and in vivo (mice) antiviral activity against influenza, Chikungunya and enterovirus 71, possibly by downregulating autophagy and the MEK/ERK signaling pathway ([@bib28], [@bib28]). Cyclosporine A (IC50: 3.0 μM and SI: \>29) was shown to be very effective in inhibiting two different coronaviruses *in vitro*, human coronavirus 229E (HCoV-229E) and mouse hepatitis virus (MHV) but not SARS-CoV ([@bib10]). Although the exact mechanism by which cyclosporine A inhibits coronavirus replication remains to be established, an early blockage of viral RNA and protein synthesis has been suggested ([@bib10]).Table 1Antiviral activity of post-infection treatment with candidate molecules against SARS-CoV-2 *in vitro*.Table 1Drug classDrug indicationCAS NumberIC50 ($\mu$M)CC50 ($\mu$M)SIRemdesivirAntimetabolites\
Antiviral agentsTreatment of Ebola virus disease1809249-37-30.987275278.62LopinavirAntiviral agentsTreatment of HIV-infection192725-17-05.246458.57ChloroquineAntimalarial agentsTreatment of malaria, rheumatoid arthritis, glioma54-05-71.38238172.46BerberineAlkaloidTreatment of parasitic and fungal infections2086-83-110.577\>400\>37.84Cyclosporine AEnzyme inhibitors\
Immunosuppressive agentsProphylaxis of organ rejection, treatment of rheumatoid arthritis & dermatologic diseases59865-13-33.048\>90\>29.53Arbidol (umifenovir)Antiviral agentsTreatment of Influenza infection131707-25-03.5377521.20Diltiazemantihypertensive & vasodilating\
agentsManagement of hypertension42399-41-7\>45424\<9.42RibavirinHepatitis C & antiviral agentsTreatment of HCV infection36791-04-5\>10\>100ndFavipiravirAntiviral agentsTreatment of Influenza infection259793-96-9\>100631\<6.31Fig. 1**Evaluation of antiviral activity of six drug candidates against SARS-CoV-2 *in vitro***. Vero E6 cells were infected by SARS-CoV-2 at a MOI of 0.01 and treated 1 h post infection (hpi) with serial dilutions of remdesivir, lopinavir, chloroquine, berberine, cyclosporine A and arbidol (umifenovir). Viral production was measured 48 hpi and expressed in relative values compared to the vehicle-treated control. The impact of treatment on cell viability was assessed by MTS assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega), and expressed in relative values compared to control. Cell viability measurements were performed to ensure that molecular viral quantification was performed within a non-cytotoxic concentration range that could bias the measurement.Fig. 1

There is arguably a consensus among virologists that combining two compounds with antiviral activity and different viral or cellular targets could result in better virological and physiological responses than those of antiviral monotherapy, for which we decided to explore this hypothesis in the case of SARS-CoV-2. Provided recent results of clinical trials failed to show a therapeutic benefit of the use of either the lopinavir-ritonavir association or chloroquine (or its derivative hydroxychloroquine) in COVID-19 patients ([@bib3]; [@bib5]; [@bib19]), we then selected remdesivir as the main antiviral agent for our drug combination studies. Following the same infection protocol described above, remdesivir dose-response experiments were repeated in the presence of berberine or diltiazem, given their expected host-directed antiviral properties. Alternatively, berberine and diltiazem dose-response curves were performed in the presence of different fixed concentrations of remdesivir. Our results show that the presence of 12.5 μM berberine induces a shift of the remdesivir dose-response towards lower drug concentration values ([Fig. 2](#fig2){ref-type="fig"} A, left panel), as evidenced by a \>2-fold reduction of remdesivir IC50 (0.41 μM *versus* 0.99 μM), with the associated increase on the SI ([Table 2](#tbl2){ref-type="table"} ). A similar trend was observed when we analyzed the berberine dose-response profile in the presence of 0.625 μM remdesivir but not at higher remdesivir concentrations ([Fig. 2](#fig2){ref-type="fig"}A, right panel and [Table 2](#tbl2){ref-type="table"}). To further explore this combination, we used SynergyFinder ([@bib16]) to calculate and visualize synergy scores, using a wider range of remdesivir/berberine concentrations spanning 24 different pairwise combinations. Interestingly, although the dose-response matrix shows a large range of pairwise combination with significant inhibitory effect ([Fig. 2](#fig2){ref-type="fig"}B), calculated Loewe synergy scores ([Fig. 2](#fig2){ref-type="fig"}C) account for a strong antagonism between remdesivir and berberine, with negative values distributed all throughout the synergy map regardless of drug concentrations ([Fig. 2](#fig2){ref-type="fig"}B and **C**). Following an analogous approach, the presence of diltiazem induced a stronger shift in the dose-response curve of remdesivir ([Fig. 3](#fig3){ref-type="fig"} A, left panel), with an up to 8.5-fold reduction of remdesivir IC50 values (0.12 μM *versus* 0.99 μM in presence of 11.5 μM diltiazem) and the consequent SI increase ([Table 3](#tbl3){ref-type="table"} ). A similar trend was observed for diltiazem dose-response curves in the presence of remdesivir ([Fig. 3](#fig3){ref-type="fig"}A, right panel). SynergyFinder analysis revealed a clear synergistic inhibitory effect of the combination, driven mainly by remdesivir but also by diltiazem, as shown by both the dose-response matrix ([Fig. 3](#fig3){ref-type="fig"}B) and the three-dimensional synergy map ([Fig. 3](#fig3){ref-type="fig"}C), with mean Loewe synergy scores of 12 and peak values above 50. Similar results were obtained using the Zero Interaction Potency (ZIP), Highest Single Agent (HAS), and Bliss independence models. Interestingly, the Loewe synergy scores obtained were quite high in comparison to the previously published synergistic combination of remdesivir and emetine ([@bib6]).Fig. 2**Evaluation of remdesivir-berberine combined treatment against SARS-CoV-2 *in vitro***. **A.** Vero E6 cells were infected by SARS-CoV-2 at a MOI of 0.01 and treated 1 hpi with serial dilutions of remdesivir in the presence of different fixed concentrations of berberine (A, left panel) or, alternatively, serial dilutions of berberine in the presence of different fixed concentrations of remdesivir (A, right panel). Viral production was measured 48 hpi and expressed in relative values compared to the vehicle-treated control. **B**. Dose-response percent inhibition matrix of single and combined remdesivir-berberine treatments **C.** Interaction landscape between remdesivir and berberine as calculated using the Loewe additive model. Areas with synergy scores of −10 or lower (green) represent zones of drug antagonism.Fig. 2Table 2**Inhibitory effect of remdesivir-berberine combined treatment against SARS-CoV-2 *in vitro.*** For each experimental condition, IC50, CC50 and the corresponding SI values are listed.Table 2Combination treatmentIC50 ($\mu$M)CC50 ($\mu$M)SIRemdesivir0.987275278.62Remdesivir\
+\
Berberine 12.5 $\mu$M0.409264645.47Berberine10.577\> 400\> 37.84Berberine\
+\
Remdesivir 0.625 $\mu$M6.95\> 57.55Berberine\
+\
Remdesivir 2.5 $\mu$M8.237\> 48.56Fig. 3**Synergistic effect of remdesivir-diltiazem combined treatment against SARS-CoV-2 *in vitro***. **A.** Vero E6 cells were infected by SARS-CoV-2 at a MOI of 0.01 and treated 1 hpi with serial dilutions of remdesivir in the presence of different fixed concentrations of diltiazem (A, left panel) or, alternatively, serial dilutions of diltiazem in the presence of different fixed concentrations of remdesivir (A, right panel). Viral production was measured 48 hpi and expressed in relative values compared to the vehicle-treated control. **B**. Dose-response percent inhibition matrix of single and combined remdesivir-diltiazem treatments **C.** Interaction landscape between remdesivir and diltiazem as calculated using the Loewe additive model. Areas with synergy scores of 10 or higher (red) represent zones of drug synergy.Fig. 3Table 3**Inhibitory effect of remdesivir-diltiazem combined treatment against SARS-CoV-2 *in vitro.*** For each experimental condition, IC50, CC50 and the corresponding SI values are listed.Table 3Combination treatmentIC50 ($\mu$M)CC50 ($\mu$M)SIRemdesivir0.987275278.62Remdesivir\
+\
Diltiazem 5.62 $\mu$M0.627267425.83Remdesivir\
+\
Diltiazem 11.5 $\mu$M0.1162301.72Remdesivir\
+\
Diltiazem 22.5 $\mu$M0.2281171.05Diltiazem\>45424\<9.42Diltiazem\
+\
Remdesivir 0.625 $\mu$M5.26841478.59Diltiazem\
+\
Remdesivir 1.25 $\mu$M1.892218.81Diltiazem\
+\
Remdesivir 2.5 $\mu$M0.554747.29

In conclusion, our study demonstrated the *in vitro* efficacy against SARS-CoV-2 of broad-spectrum antivirals such as Remdesivir, Lopinavir, chloroquine, Arbidol and Ribavirin and repurposable host-targeted drug candidates such as Berberine or cyclosporine A in monotherapy. As already reported by our group and others for the treatment of severe forms of influenza infection ([@bib11]; [@bib23]), drug combination highlighted the added value of combining drugs with different modes of action as a strategy to improve antiviral therapy. From this perspective, the remdesivir/diltiazem combination seems particularly interesting for the treatment of COVID-19, with a synergistic antiviral affect against SARS-CoV-2 in a wide dose range that remains below reported remdesivir therapeutic plasma concentrations. Although berberine, cyclosporine A and the remdesivir-diltiazem combination showed interesting potential as SARS-CoV-2 inhibitors, we are nonetheless aware of the inherent limits of the Vero E6 *in vitro* model, which may not accurately reflect the potential efficacy of antiviral molecules in more physiological models. In addition, the *a priori* counter-intuitive antagonistic effect observed for the remdesivir/berberine combination further illustrates the challenge of proposing effective drug combinations based on individual drug-efficacy data. We therefore expect our data constitute a starting point for further validation of selected candidates in more complex and biologically relevant pre-clinical models of SARS-CoV-2 infection before consideration for evaluation in the clinical setting.
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